Drug Profile
Carbetocin intranasal - Ferring Pharmaceuticals/Levo Therapeutics
Alternative Names: ACP-101; FE-992097; LV 101Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Developer Levo Therapeutics
- Class Antihaemorrhagics; Oxytocics; Posterior pituitary hormones
- Mechanism of Action Oxytocin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Prader-Willi syndrome
Most Recent Events
- 31 Dec 2023 Carbetocin intranasal receives Rare Paediatric Disease designation from the US FDA for Prader-Willi syndrome, before December 2023
- 30 Nov 2023 Phase-III clinical trials in Prader-Willi syndrome (In children, In adolescents, In adults) (Intranasal)
- 02 Aug 2023 Levo therapeutics plans a phase III trial for Prader-Willi syndrome in the fourth quarter of 2023